A Case of Bullous Pemphigoid Associated With Nivolumab Therapy-Reference-Cited by-同舟云学术

A Case of Bullous Pemphigoid Associated With Nivolumab Therapy

Published:2022-05-07 Issue: Volume: Page:
ISSN:2168-8184
Container-title:Cureus
language:en
Short-container-title:

Author:

Gotera Nico,Weilg Pablo,Heleno Caio,Ferrari-Gabilondo Natalia

Publisher

Cureus, Inc.

Subject

Aerospace Engineering

Reference12 articles.

1. Nivolumab;Rendon A,2021

2. A case of nivolumab-induced bullous pemphigoid: review of dermatologic toxicity associated with programmed cell death protein-1/programmed death ligand-1 inhibitors and recommendations for diagnosis and management;Lopez AT;Oncologist,2018

3. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors;Lopez AT;Int J Dermatol,2018

4. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. (2021). Accessed. April 20, 2022: https://safetyprofiler-ctep.nci.nih.gov/safety-profiler/static/#/home/(body:ctcDictionary)?version=5.0.

5. Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy;Wang LL;JAMA Dermatol,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid;Investigational New Drugs;2023-09-29

2. Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience;Frontiers in Medicine;2023-07-20

3. Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer;Frontiers in Oncology;2023-03-14